Development of a CHO cell line for stable production of recombinant antibodies against human MMP9

被引:7
|
作者
Ryu, Jina [1 ]
Kim, Eun-Jung [2 ]
Kim, Joo-Kyung [1 ]
Park, Tai Hyun [1 ,2 ,3 ]
Kim, Byung-Gee [1 ,2 ,3 ]
Jeong, Hee-Jin [4 ]
机构
[1] Seoul Natl Univ, Interdisciplinary Program Bioengn, Seoul 08826, South Korea
[2] Seoul Natl Univ, Inst Chem Proc, Sch Chem & Biol Engn, Seoul 08826, South Korea
[3] Seoul Natl Univ, BioMAX N Bio Inst, Inst Bioengn, Seoul 08826, South Korea
[4] Hongik Univ, Dept Biol & Chem Engn, Sejong 30016, South Korea
基金
新加坡国家研究基金会;
关键词
Matrix metalloproteinase 9; Recombinant antibody; CHO cell line; MONOCLONAL-ANTIBODIES; GELATINASE B; PROTEIN; MATRIX-METALLOPROTEINASE-9;
D O I
10.1186/s12896-022-00738-6
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Background Human matrix metalloproteinase 9 (hMMP9) is a biomarker in several diseases, including cancer, and the need for developing detectors and inhibitors of hMMP9 is increasing. As an antibody against hMMP9 can be selectively bound to hMMP9, the use of anti-MMP9 antibody presents new possibilities to address hMMP9-related diseases. In this study, we aimed to establish a stable Chinese hamster ovary (CHO) cell line for the stable production of antibodies against hMMP9. Results Weconstructed recombinant anti-hMMP9 antibody fragment-expressing genes and transfected these to CHO cells. We chose a single clone, and successfully produced a full-sized antibody against hMMP9 with high purity, sensitivity, and reproducibility. Subsequently, we confirmed the antigen-binding efficiency of the antibody. Conclusions We developed a novel recombinant anti-hMMP9 antibody via a CHO cell-based mammalian expression system, which has a high potential to be used in a broad range of medical and industrial areas.
引用
收藏
页数:8
相关论文
共 50 条
  • [41] Microrna-155 Inhibits Cell Migration in Human Cardiomyocyte Progenitor Cells Mediated by Mmp2 and Mmp9
    Liu, Jia
    van Mil, Alain
    Doevendans, Pieter A.
    Sluijter, Joost P.
    CIRCULATION, 2010, 122 (21)
  • [42] Rapid recombinant protein production from piggyBac transposon-mediated stable CHO cell pools
    Balasubramanian, Sowmya
    Matasci, Mattia
    Kadlecova, Zuzana
    Baldi, Lucia
    Hacker, David L.
    Wurm, Florian M.
    JOURNAL OF BIOTECHNOLOGY, 2015, 200 : 61 - 69
  • [43] Robotic selection for the rapid development of stable CHO cell lines for HIV vaccine production
    O'Rourke, Sara M.
    Byrne, Gabriel
    Tatsuno, Gwen
    Wright, Meredith
    Yu, Bin
    Mesa, Kathryn A.
    Doran, Rachel C.
    Alexander, David
    Berman, Phillip W.
    PLOS ONE, 2018, 13 (08):
  • [44] CHARACTERIZATION OF RECOMBINANT GLYCOSYLATED HUMAN INTERLEUKIN-2 PRODUCED BY A RECOMBINANT PLASMID TRANSFORMED CHO CELL-LINE
    FERRARA, P
    PECCEU, F
    MARCHESE, E
    VITA, N
    ROSKAM, W
    LUPKER, J
    FEBS LETTERS, 1987, 226 (01) : 47 - 52
  • [45] TRANSFORMING GROWTH FACTOR BETA HAS DUAL EFFECTS ON MMP9 AND uPA EXPRESSION IN HTR-8/SVneo HUMAN TROPHOBLASTIC CELL LINE
    Novoa Herran, Sandra Susana
    Castelblanco, Mariela
    Sanchez-Gomez, Myriam
    Umana Perez, Adriana
    ACTA BIOLOGICA COLOMBIANA, 2019, 24 (01): : 26 - 37
  • [46] Calcipotriol reduced induction of MMP-9 and MMP-13 in human squamous cell carcinoma cell line
    Meephansan, Jitlada
    Komine, Mayumi
    Ohtsuki, Mamitaro
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2010, 130 : S52 - S52
  • [47] From Efficiency to Yield: Exploring Recent Advances in CHO Cell Line Development for Monoclonal Antibodies
    Majumdar, Sarmishta
    Desai, Ranjeet
    Hans, Aakarsh
    Dandekar, Prajakta
    Jain, Ratnesh
    MOLECULAR BIOTECHNOLOGY, 2025, 67 (02) : 369 - 392
  • [48] CIRSIUM OLERACEUM L. SCOP. INHIBITS CELL VIABILITY AND DECREASES SECRETION OF MATRIX METALLOPROTEINASES (MMP2 AND MMP9) IN GLIOBLASTOMA CELL LINE
    Naliwajko, Sylwia K.
    Markiewicz-Zukowska, Renata
    Moskwa, Justyna
    Kasacka, Irena
    Gromkowska-Kepka, Krystyna
    Nowakowski, Patryk
    Socha, Katarzyna
    Borawska, Maria H.
    ACTA POLONIAE PHARMACEUTICA, 2018, 75 (06): : 1363 - 1368
  • [49] Development and Characterization of New Monoclonal Antibodies against Human Recombinant CA XII
    Dekaminaviciute, Dovile
    Lasickiene, Rita
    Parkkila, Seppo
    Jogaite, Vaida
    Matuliene, Jurgita
    Matulis, Daumantas
    Zvirbliene, Aurelija
    BIOMED RESEARCH INTERNATIONAL, 2014, 2014
  • [50] Development of Human Recombinant Antibodies Against ROR1 Tumor Antigen
    Bemani, Peyman
    Moazen, Setareh
    Nadimi, Elham
    Nejatollahi, Foroogh
    REPORTS OF BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2022, 11 (02): : 282 - 288